Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

345 Press Releases
DateTitleCompany
17 Aug 12 Teva Announces Launch of Generic Actos® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
08 Aug 12 Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Aug 12 Teva Pharmaceutical Announces New Appointments of President and Chief Executive Officer, Global Operations and Executive Vice President, Community and Institutional Affairs Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Aug 12 Teva Reports Second Quarter 2012 Results Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
13 Jul 12 Teva to Report Second Quarter 2012 Financial Results on August 2, 2012 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
11 Jul 12 Teva Announces Favorable United Kingdom Court Ruling In COPAXONE® Patent Litigation Proceeding Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
30 Jun 12 Teva Announces Progress of Biologic Investigational Drugs Evaluated to Treat Neutropenia in Breast Cancer Patients Undergoing Chemotherapy Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
23 Jun 12 Teva Announces Favorable Court Ruling in COPAXONE® Patent Infringement Litigation Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
22 Jun 12 Teva Announces Launch of Generic Symbyax® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
14 Jun 12 Teva Announces Top-Line Results from GALA Phase III Trial Evaluating a New Dosage for Glatiramer Acetate Given Three Times Weekly for Relapsing-Remitting Multiple Sclerosis Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
13 Jun 12 Teva Announces AZILECT® (Rasagiline Tablets) Data to Be Presented at the 16th Annual International Congress of Parkinson’s Disease and Movement Disorders Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Jun 12 Teva to Present at the Jefferies 2012 Global Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Jun 12 Teva to Present at the Goldman Sachs 33rd Annual Global Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Jun 12 Teva Pharmaceutical Industries Ltd. Chairman of the Board Dr. Phillip Frost Purchases 1 Million Teva Shares Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
31 May 12 Teva Begins Trading on the New York Stock Exchange Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
30 May 12 Teva to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
24 May 12 Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
24 May 12 Teva to Host Conference Call and Webcast on May 24, 2012 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
18 May 12 Teva’s Board of Directors Votes to Re-Elect Dr. Phillip Frost as Chairman of the Board Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
09 May 12 Teva Issues Updated Conference Call Information for First Quarter 2012 Financial Results on May 9, 2012 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
09 May 12 Teva Reports First Quarter 2012 Results Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
09 May 12 Teva Appoints Michael Hayden as President of Global Research and Development and Chief Scientific Officer Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
30 Apr 12 Teva settles Nuvigil litigation with Mylan Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
26 Apr 12 Preliminary Data Suggest Spasticity May Be Reduced in Relapsing-Remitting Multiple Sclerosis Patients Who Transitioned to Teva’s COPAXONE® Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
20 Apr 12 Teva to Report First Quarter 2012 Financial Results on May 9, 2012 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
18 Apr 12 Teva Announces New Data on Central Nervous System Products to Be Presented at 2012 American Academy of Neurology Annual Meeting Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Apr 12 FDA Decides Teva is Sole First-to-File on Provigil® Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Apr 12 Teva Announces Pricing of EUR 1 Billion and CHF 450 Million of Senior Notes, and the Closing of a New JPY 100 Billion Unsecured Syndicated Facility Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Apr 12 Teva Announces Launch of Generic Avapro® and Generic Avalide® in the United States; Awarded 180-Day Period of Marketing Exclusivity Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
30 Mar 12 Teva Announces Launch of Authorized Generic of Provigil® Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.